1. Home
  2. CTW vs CRBU Comparison

CTW vs CRBU Comparison

Compare CTW & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CTW

CTW Cayman Class A Ordinary Shares

N/A

Current Price

$2.48

Market Cap

171.6M

Sector

Technology

ML Signal

N/A

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$1.89

Market Cap

166.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTW
CRBU
Founded
2013
2011
Country
Japan
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
171.6M
166.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CTW
CRBU
Price
$2.48
$1.89
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.75
AVG Volume (30 Days)
17.5K
2.6M
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.64
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.63
Revenue Next Year
N/A
$10.93
P/E Ratio
$22.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$1.38
52 Week High
$3.14
$3.53

Technical Indicators

Market Signals
Indicator
CTW
CRBU
Relative Strength Index (RSI) 52.76 52.69
Support Level $1.96 $1.73
Resistance Level $3.05 $2.02
Average True Range (ATR) 0.31 0.13
MACD 0.01 0.04
Stochastic Oscillator 47.52 57.27

Price Performance

Historical Comparison
CTW
CRBU

About CTW CTW Cayman Class A Ordinary Shares

CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Share on Social Networks: